SCHEMBL364306

SCHEMBL364306

Oc1cnc(N2CCCCC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 3/20 0.43
TSHR P16473 1/20 0.41
HDAC6 Q9UBN7 1/20 0.39
USP2 O75604 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 3/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 1/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26077215 1.00 POLB (0.46) POLBSMN1; SMN2ALDH1A1TSHRHDAC6
SCHEMBL15952948 0.98 ALDH1A1 (0.44) POLBSMN1; SMN2ALDH1A1TSHRHDAC6
SCHEMBL15038306 0.78 HDAC3 (0.51) ALDH1A1TSHRHDAC6USP2TDP1
SCHEMBL10413396 0.78 POLB (0.62) POLBALDH1A1TSHRHDAC6MAPK1
SCHEMBL2739054 0.78 ALDH1A1 (0.59) POLBSMN1; SMN2ALDH1A1TSHRHDAC6
SCHEMBL13798271 0.77 TSHR (0.45) POLBSMN1; SMN2ALDH1A1TSHRHDAC6
SCHEMBL12874013 0.77 ALDH1A1 (0.47) POLBSMN1; SMN2ALDH1A1TSHRUSP2
SCHEMBL3611548 0.77 TSHR (0.49) POLBSMN1; SMN2ALDH1A1TSHRHDAC6
SCHEMBL365996 0.77 TSHR (0.49) POLBSMN1; SMN2ALDH1A1TSHRHDAC6
SCHEMBL1984161 0.77 ALDH1A1 (0.43) POLBSMN1; SMN2ALDH1A1TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
CN-105431149-B Neuroprotective multifunctional antioxidants and their monofunctional analogs 彼得·F·卡罗 2019-06-11 CN disclosed
EP-2956140-B1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS KADOR PETER F (US) 2018-07-11 EP disclosed
EP-2956140-B1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS KADOR PETER F (US) 2018-07-11 EP disclosed
US-9994552-B2 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION (US) 2018-06-12 US disclosed
US-20170029409-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION 2017-02-02 US disclosed
US-9499522-B2 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION (US) 2016-11-22 US disclosed
CN-105431149-A Neuroprotective multifunctional antioxidants and their monofunctional analogs KADOR PETER F 2016-03-23 CN disclosed
EP-2956140-A1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS Kador, Peter F. (US) 2015-12-23 EP disclosed
US-8877766-B2 Neuroprotective multifunctional antioxidants and their monofunctional analogs BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2014-11-04 US disclosed
WO-2014126596-A1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS KADOR PETER F (US) 2014-08-21 WO disclosed
US-20140235858-A1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2014-08-21 US disclosed
US-20140235858-A1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2014-08-21 US disclosed
US-8592629-B2 Sulfonamide derivatives as Nav 1.7 inhibitors PFIZER LIMITED (GB) 2013-11-26 US disclosed
EP-2593432-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010183-A1 Chemical Compounds SCN1A, SCN1B, SCN7A POLB 4442/4885SMN1; SMN2 595/4885ALDH1A1 1098/4885
US-20170029409-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT KIT, APC, CKMT1A; CKMT1B POLB 231/4885SMN1; SMN2 194/4885ALDH1A1 629/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 POLB 2731/4885SMN1; SMN2 2206/4885ALDH1A1 3733/4885
US-20140235858-A1 NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS SOD1, SOD3, NFE2L2 POLB 625/4885SMN1; SMN2 282/4885ALDH1A1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.